EnChannel Medical Ltd.

EnChannel operates in cardiac electrophysiology, focusing on atrial-fibrillation mapping and pulsed-field ablation rather than serving as a general medical-device supplier. Its stated differentiation is workflow integration: the company combines 3D mapping with PFA ablation and describes a full-chamber 5D mapping approach. The DePolar Mapping System adds contact and noncontact mapping capabilities, while NanoAblate offers both single-shot and large-focal catheter options. The 2025 acquisition of Acutus Medical’s AcQMap assets broadens the company’s mapping technology base and may strengthen its ability to compete for electrophysiology lab adoption. EnChannel has also attracted $110.2 million across Series A and Series B financing, including participation from Lilly Asia Ventures, Longpan Investment, Longzhu Capital, and Lapam Capital.

EnChannel’s disclosed trajectory shows a progression from platform formation to larger-scale technology expansion. Founded in 2020, the company raised $27.9 million in a Series A announced on Aug 1, 2023, with Lilly Asia Ventures and Longpan Investment as leads. It then raised $82.3 million in a Series B announced on Apr 23, 2025, more than doubling its cumulative disclosed financing to $110.2 million. The Series B was tied to full-chamber 5D atrial-fibrillation mapping and personalized PFA therapy, suggesting an increased emphasis on integrated procedural solutions. The Jun 1, 2025 acquisition of Acutus Medical’s AcQMap electrophysiology assets was a second inflection point, adding external mapping capabilities to the company’s own DePolar and NanoAblate product strategy. The combination of financing and acquisition indicates an effort to accelerate product development and broaden clinical utility. Growth appears technology- and capital-led rather than demonstrably commercial at this stage.